The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InFederal records have revealed that FDA and CDC officials identified potential stroke risks associated with Pfizer's bivalent booster as early as October 2022. According to Senate investigators, CDC data flagged 226 stroke cases between August 2022 and February 2023, yet regulators allegedly withheld this information while publicly maintaining vaccine safety. Documents indicate that the Department of Health and Human Services (HHS) even commissioned a private contractor for a secret internal probe dubbed "The Stroke Project." The investigation suggests that safety signals were suppressed to avoid impacting vaccine uptake among the public. These allegations pose significant litigation and reputational risks for Pfizer and BioNTech, potentially weighing on the broader biotech sector. Market participants are closely monitoring the fallout as government scrutiny intensifies regarding transparency and public health protocols.